Skip to content

Imagery Rescripting for Posttraumatic Nightmares in Rural Operation Enduring Freedom (OEF)/Operation Iraqi Freedom (OIF) Veterans With Posttraumatic Stress Disorder (PTSD)

Imagery Rescripting for Posttraumatic Nightmares in Rural Operation Enduring Freedom (OEF)/Operation Iraqi Freedom (OIF) Veterans With Posttraumatic Stress Disorder (PTSD)

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00837382
Enrollment
7
Registered
2009-02-05
Start date
2010-01-31
Completion date
2010-08-31
Last updated
2010-09-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sleep Disorders, Stress Disorders, Post-Traumatic

Brief summary

Many service members returning from Iraq and Afghanistan have difficulties adjusting back to civilian life. Research shows that symptoms of posttraumatic stress disorder (PTSD) are particularly high in returning Operation Enduring Freedom (OEF)/Operation Iraqi Freedom (OIF) veterans, and that combat-related nightmares and sleep disturbances are common in veterans with PTSD. This is of concern because people with these problems will often use unhealthy ways of coping. Although combat-related nightmares and difficulty sleeping are highly distressing, there are helpful treatments that do not involve taking medication. One of these treatments teaches specific skills to help people improve their sleep habits and to change their nightmares so that they are less upsetting. This treatment can be very helpful and research shows that people experience decreases in the frequency and severity of their nightmares, decreased symptoms of depression and PTSD, and improved sleep quality and quantity after completing treatment. However, because this treatment has only been studied with civilians, it is not clear how well this treatment works for returning veterans. This study tests how well this treatment works in treating combat nightmares in veterans who also have PTSD from experiencing a traumatic event.

Interventions

BEHAVIORALMEDVAMC Nightmare Treatment

Veteran Nightmare Treatment Using Imagery Rescripting

BEHAVIORALTelepsychiatry Nightmare Treatment

Veteran Nightmare Treatment Using Imagery Rescripting Through Videoconferencing

Sponsors

US Department of Veterans Affairs
Lead SponsorFED

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 64 Years
Healthy volunteers
No

Inclusion criteria

Patients for the open trial will be 1. OEF/OIF veterans (aged 18-64); 2. English-speaking; 3. currently enrolled in the Trauma Recovery Program (TRP) at the Michael E. DeBakey Veteran Affairs Medical Center (MEDVAMC); 4. reporting at least one combat or war zone associated PTNM in the past week; 5. have an existing PTSD International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM); and 6. consenting to be in an open trial for treatment of PTNM. In addition, patients must agree to allow their assessment and therapy sessions to be video/audiotaped for the purposes of supervision. Pilot Study: Patients for the pilot study will be 1. OEF/OIF veterans (aged 18-64); 2. English-speaking; 3. currently enrolled in the Conroe CBOC for their primary or mental health care; 4. reporting at least one combat or war zone associated PTNM in the past week; 5. have an existing PTSD ICD-9-CM diagnosis; and 6. consenting to be in the pilot study for treatment of PTNM. In addition, patients must agree to allow their assessment and therapy sessions to be video/audiotaped for the purposes of supervision.

Exclusion criteria

Patients will be excluded for the following reasons: 1. current active suicidal/homicidal ideation and intent; 2. current substance dependence; 3. a diagnosis of bipolar or psychosis; 4. active participation in another psychosocial treatment for PTSD; 5. prescribed the medication Prazosin (a psychotropic medication for the treatment of nightmares). Patients interested in receiving the intervention will not be excluded if they are taking psychotropic medication (except for Prazosin) and may continue to take their medication as prescribed throughout the study.

Design outcomes

Primary

MeasureTime frame
Clinician Administered PTSD Scale (CAPS), Posttraumatic Stress Symptom Scale-Self-Report (PSS-SR) & Beck Depression Inventory-II (BDI-II)Baseline & post-treatment

Secondary

MeasureTime frame
Treatment Evaluation Inventory (TEI)Post-treatment
Client Satisfaction Questionnaire (CSQ)Post-treatment
Mini-International Neuropsychiatric Interview (MINI)Baseline
The Pittsburgh Sleep Quality Index-Addendum for PTSD (PSQI)Baseline & post-treatment
Trauma Related Nightmare Survey (TRNS).Baseline & post-treatment
Posttraumatic Cognitions Inventory (PTCI).Baseline & post-treatment

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026